From a legal standpoint, a physician who provides BPC-157 outside of a trial could indeed be treading into malpractice territory
Tam said, "which may be why there's so much interest in these newer peptides
Expert Opinion on Therapeutic Patents, 31(5), 401414
Its role in chronic obstructive pulmonary disease and other disease developments
We postulated that 5FU treatment may promote an enhanced dependency on mitochondrial metabolism, and, in turn, mitochondrial metabolism may dictate sensitivity to 5FU
If the WADA considers it doping it must be doing something, right?? So we are left in a modern clinical trap: a compound with a large preclinical footprint and an even larger cultural footprint, but a striking lack of rigorous translational evidence